Skip to content
← All interventions
Senolytic candidate

Fisetin

Automated longevity evidence pipeline intervention.

Where the science stands

This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.

Evidence depth 69 / 100

Research path

From biological idea to human evidence

These stages show different kinds of evidence for Fisetin. Moving through them does not mean an intervention is proven to slow aging.

  1. 1

    Biological idea

    Reviewing animal and laboratory research…

  2. 2

    Human testing

    15 direct aging trial links and 2 related trial links tracked. A trial count describes research activity, not benefit.

  3. 3

    What results show

    0 beneficial, 3 neutral and 0 harmful result links interpreted; 3 remain unresolved.

  4. 4

    Still unanswered

    Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.

How AgeBeacon evaluates evidence →

Beyond human trials

The bigger longevity story

Loading animal and laboratory evidence…

Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.

Signals we're watching

What human studies are measuring

Biological aging

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 0 remain unknown.

Research depth

Human evidence picture

Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.

15
Direct aging trials
2
Indirect relevant trials
18
Publications linked
3
Results publications

Interpreted results

Beneficial
0
Neutral
3
Harmful
0
Unknown / unresolved
3

Population relevance

Healthy / aging
3
Disease-specific
2

Safety evidence

0

Trials currently identified with safety-result data.

Go to the source

Studies & publications

Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.

Inflammation and Stem Cells in Diabetic and Chronic Kidney DiseaseNCT03325322INTERVENTIONAL · PHASE2 · 30 participants · SUSPENDEDTargeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansNCT04313634INTERVENTIONAL · PHASE2 · 74 participants · COMPLETEDFisetin in Mild Alzheimer's DiseaseNCT07279714INTERVENTIONAL · PHASE2 · 5 participants · COMPLETEDSenolytic Agent Improve the Benefit of Platelet-Rich Plasma and LosartanNCT05025956INTERVENTIONAL · PHASE1/PHASE2 · 68 participants · UNKNOWNFisetin to Reduce Senescence and Mobility Impairment in PADNCT06399809INTERVENTIONAL · PHASE2 · 34 participants · RECRUITINGFisetin to Improve Vascular Function in Older AdultsNCT06133634INTERVENTIONAL · PHASE1/PHASE2 · 70 participants · ACTIVE_NOT_RECRUITINGFisetin Supplementation for Healthy AgingNCT07195318INTERVENTIONAL · NA · 120 participants · RECRUITINGEvaluation of Urolithin A and Fisetin on Improving Sleep and Aging BiomarkersNCT06990256INTERVENTIONAL · NA · 83 participants · ACTIVE_NOT_RECRUITINGVIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional SupplementsNCT04994561INTERVENTIONAL · PHASE1 · WITHDRAWNPilot Trial of Fisetin in Healthy Volunteers and Older Patients With MultimorbidityNCT06431932INTERVENTIONAL · PHASE1/PHASE2 · 60 participants · RECRUITINGEvaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging EffectsNCT07678346INTERVENTIONAL · NA · 70 participants · NOT_YET_RECRUITINGGetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and DepressionNCT05482672INTERVENTIONAL · PHASE2/PHASE3 · WITHDRAWNFarr JN, Monroe DG, Atkinson EJ, Froemming MN, Ruan M, LeBrasseur NK, Khosla S. Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging Cell. 2025 May;24(5):e14489. doi: 10.1111/acel.14489. Epub 2025 Jan 17.PMID 39823170Results publicationFarr JN, Atkinson EJ, Achenbach SJ, Volkman TL, Tweed AJ, Vos SJ, Ruan M, Sfeir J, Drake MT, Saul D, Doolittle ML, Bancos I, Yu K, Tchkonia T, LeBrasseur NK, Kirkland JL, Monroe DG, Khosla S. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024 Sep;30(9):2605-2612. doi: 10.1038/s41591-024-03096-2. Epub 2024 Jul 2.PMID 38956196Results publicationBian X, Snow ZK, Zinn CJ, Gowan CC, Conley SM, Bratulin AL, Elhusseiny KM, Miller J, Tchkonia T, Kirkland JL, Lerman LO, Hickson LJ. Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease. Kidney360. 2025 Mar 28;6(8):1278-1291. doi: 10.34067/KID.0000000776.PMID 40152935Results publicationBentley G, Biant LC, Carrington RW, Akmal M, Goldberg A, Williams AM, Skinner JA, Pringle J. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J Bone Joint Surg Br. 2003 Mar;85(2):223-30. doi: 10.1302/0301-620x.85b2.13543.PMID 12678357Linked publicationda Costa BR, Hari R, Juni P. Intra-articular Corticosteroids for Osteoarthritis of the Knee. JAMA. 2016 Dec 27;316(24):2671-2672. doi: 10.1001/jama.2016.17565.PMID 28027351Linked publicationBannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. doi: 10.1016/j.joca.2019.06.011. Epub 2019 Jul 3.PMID 31278997Linked publicationGel'man SI. [The choice of rational modes of artificial pulmonary ventilation in cerebral operations]. Eksp Khir Anesteziol. 1965 Nov-Dec;10(6):57-60. No abstract available. Russian.PMID 5873863Linked publicationMilstein C, Clegg JB, Jarvis JM. C-terminal half of immunoglobulin lambda-chains. Nature. 1967 Apr 15;214(5085):270-2. doi: 10.1038/214270a0. No abstract available.PMID 4166495Linked publicationStokes J, Drury RA. Gordon Roy Cameron. J Clin Pathol. 1967 Jan;20(1):5-6. doi: 10.1136/jcp.20.1.5. No abstract available.PMID 5334539Linked publicationNiemineva K. [1897--a landmark in Finnish medical literature]. Duodecim. 1966;82(17):823-7. No abstract available. Finnish.PMID 5331226Linked publicationMartinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002 Aug;10(2):417-26. doi: 10.1016/s1097-2765(02)00599-3.PMID 12191486Linked publicationPanich V, Sungnate T, Na-Nakorn S. Acute intravascular hemolysis and renal failure in a new glucose-6-phosphate dehydrogenase variant: G-6-PD Siriraj. J Med Assoc Thai. 1972 Dec;55(12):726-31. No abstract available.PMID 4650733Linked publication

The big unanswered question

Can promising biology translate into meaningful healthy-aging benefits?

That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.

Confidence: lowScore model: v0.5-curated-ruleUpdated: 2026-09-21Source: live evidence database